CN101076331A - 包含烟酸受体部分促效剂的用于治疗发红和脂质相关病症的组合物 - Google Patents

包含烟酸受体部分促效剂的用于治疗发红和脂质相关病症的组合物 Download PDF

Info

Publication number
CN101076331A
CN101076331A CNA2005800375213A CN200580037521A CN101076331A CN 101076331 A CN101076331 A CN 101076331A CN A2005800375213 A CNA2005800375213 A CN A2005800375213A CN 200580037521 A CN200580037521 A CN 200580037521A CN 101076331 A CN101076331 A CN 101076331A
Authority
CN
China
Prior art keywords
niacin
analog
tetrazol
pyrazole
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800375213A
Other languages
English (en)
Chinese (zh)
Inventor
多米尼克·P·贝汉
丹尼尔·T·康诺利
杰里米·里奇曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arena Pharmaceuticals Inc
Original Assignee
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals Inc filed Critical Arena Pharmaceuticals Inc
Publication of CN101076331A publication Critical patent/CN101076331A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2005800375213A 2004-11-05 2005-11-01 包含烟酸受体部分促效剂的用于治疗发红和脂质相关病症的组合物 Pending CN101076331A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62553604P 2004-11-05 2004-11-05
US60/625,536 2004-11-05

Publications (1)

Publication Number Publication Date
CN101076331A true CN101076331A (zh) 2007-11-21

Family

ID=36046632

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800375213A Pending CN101076331A (zh) 2004-11-05 2005-11-01 包含烟酸受体部分促效剂的用于治疗发红和脂质相关病症的组合物

Country Status (7)

Country Link
US (1) US20080139628A1 (enExample)
EP (1) EP1811996A1 (enExample)
JP (1) JP2008519080A (enExample)
CN (1) CN101076331A (enExample)
AU (1) AU2005305086A1 (enExample)
CA (1) CA2584225A1 (enExample)
WO (1) WO2006052569A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
ATE440828T1 (de) 2003-11-21 2009-09-15 Arena Pharm Inc 4-oxo-4,5-dihydro-furan-2-carbonsäure und derivate und verfahren zur behandlung von stoffwechselerkrankungen mit diesen verbindungen
PL364348A1 (en) 2004-01-12 2005-07-25 PHARMENA Sp.z o.o. Application of quaternary pyridine salts as vessel protection agent
US20070021379A1 (en) 2005-07-11 2007-01-25 Pharmena North America Inc. Methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities
EP2099450A4 (en) * 2006-10-20 2011-01-26 Merck Sharp & Dohme AGONISTS OF THE NIACIN RECEPTOR, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND TREATMENT PROCEDURES
US8648103B2 (en) 2008-07-08 2014-02-11 Daiichi Sankyo Company, Limited Nitrogen-containing aromatic heterocyclyl compound
WO2011163612A1 (en) * 2010-06-24 2011-12-29 Trustees Of Tufts College Niacin mimetics, and methods of use thereof
US8450316B2 (en) 2010-06-24 2013-05-28 Trustees Of Tufts College Niacin mimetics, and methods of use thereof
CN103755637A (zh) * 2013-12-26 2014-04-30 平湖优康药物研发有限公司 一种医药中间体1,4,5,6-四氢-3-环戊并吡唑甲腈的合成工艺
US9456982B2 (en) 2014-05-18 2016-10-04 Be-Warm Llc Solid formulations of niacin to counteract cold extremities

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5268181A (en) * 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
AU5787996A (en) * 1995-04-19 1996-11-07 Lipoprotein Technologies, Inc. Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs
US6902902B2 (en) * 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
DE60327446D1 (de) * 2002-10-10 2009-06-10 Arena Pharm Inc 5-substituierte 2h-pyrazon-3-carbonsäure-derivate als antilipolytische mittel zur behandlung von stoffwechselstörungen, wie z.b. dyslipidemie
TWI258478B (en) * 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof

Also Published As

Publication number Publication date
EP1811996A1 (en) 2007-08-01
CA2584225A1 (en) 2006-05-18
AU2005305086A1 (en) 2006-05-18
WO2006052569A1 (en) 2006-05-18
US20080139628A1 (en) 2008-06-12
JP2008519080A (ja) 2008-06-05

Similar Documents

Publication Publication Date Title
CN1240699C (zh) 与趋化因子有关的疾病的治疗或预防药物
US20060122240A1 (en) Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof
WO2004033431A2 (en) Hydroxypyrazoles for use against metabolic-related disorders
CN1177844C (zh) 作为cgrp拮抗剂的新环丙烷、包含该化合物的药物及其生产方法
CN1473043A (zh) 一种利用取代的吡唑治疗变态反应的方法
CN1331591A (zh) 用作趋化因子受体5调节剂的氮杂二环烷烃
US8614222B2 (en) Methods of preventing and treating low bone mass diseases
CN1805743A (zh) 用作逆转淀粉样变性及其他与之相关疾病的rage拮抗剂
CN1238689A (zh) 玻连蛋白受体拮抗剂
MX2007008376A (es) Terapia de combinacion para el tratamiento de diabetes y condiciones relacionadas con la misma, y para el tratamiento de las condiciones aminoradas por el aumento del nivel de glp-1 en sangre.
CN1894225A (zh) 作为鞘氨醇1－磷酸(内皮分化基因)受体激动剂的(3,4－二取代)丙酸酯
CN1871239A (zh) β－联蛋白/TCF激活转录的调节
CN1751038A (zh) 作为葡萄糖代谢调节剂的经取代芳基和杂芳基衍生物及葡萄糖代谢失调的预防和治疗
CN1946391A (zh) 包含α－2－δ配体的组合
CN101076331A (zh) 包含烟酸受体部分促效剂的用于治疗发红和脂质相关病症的组合物
US20180057466A1 (en) Triazole derivatives and their use as pde4 activators
CN1516706A (zh) 人g蛋白偶联受体的内源性和非内源性形式
US9182414B2 (en) Methods for identifying a GLP-1 secretagogue
CN101027560A (zh) 用于治疗高血糖症和相关病症的人类g蛋白偶合受体及其调节物
CN1117092C (zh) 氮杂双环化合物,其药物组合物及医药用途
CN1867562A (zh) 四唑衍生物和其代谢相关的疾病的治疗方法
CN1780612A (zh) 利用5ht2c激动剂治疗失禁
CN1364167A (zh) G蛋白偶联受体6的小分子调节剂
CN1720046A (zh) 作为抗脂解药用于治疗血脂异常等代谢相关疾病的5－取代的2h－吡唑－3－甲酸衍生物
CN101052420A (zh) 用于治疗自体免疫疾病的并用药

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20071121